S&P 500 cuts losses as Nvidia climbs ahead of results
Investing.com -- Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) reported better-than-expected first quarter 2025 results and raised its full-year revenue guidance, sending shares up 3.3% in after-hours trading.
The biopharmaceutical company posted adjusted earnings per share of -$0.30, beating analyst estimates by $0.01. Revenue for the quarter surged 61% YoY to $111.6 million, significantly surpassing the consensus estimate of $98.02 million.
Mirum’s strong performance was driven by robust sales growth across its product portfolio. LIVMARLI net product sales jumped 71% YoY to $73.2 million, while Bile Acid Medicines net product sales increased 47% YoY to $38.4 million.
"It’s been a strong start to the year with commercial growth and multiple milestones achieved across our pipeline," said Chris Peetz, CEO of Mirum Pharmaceuticals. "We’re pleased with the FDA’s approval of LIVMARLI’s tablet formulation, which provides more options for the ALGS and PFIC community in the U.S. in the form of a convenient single tablet dose."
Following the strong quarter, Mirum raised its full-year 2025 revenue guidance to a range of $435 million to $450 million, up from its previous forecast and above the analyst consensus of $427.8 million.
The company also reported progress in its clinical pipeline, with the VISTAS study of volixibat in primary sclerosing cholangitis expected to complete enrollment in the third quarter of 2025.
As of March 31, 2025, Mirum had $298.6 million in cash, cash equivalents, and investments, providing a solid financial foundation for its ongoing operations and research initiatives.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.